Skip to main content
OpenTrials
Completed

NCT Number: NCT01906177

A Prospective Munti-center Study on VANGUARD™ PS Total Knee Replacement System

The primary objectives of this pilot clinical study include:

* Evaluate clinical outcomes and quality of life on patients who received Vanguard PS Total Knee in Korean population * Evaluate safety of Vanguard PS Total Knee in Korean population

Completed

Looking for future studies?

Notify Me

Key information

Age range

20 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Gangneung Asan Hospital, Gangneung-Si, Gangwon-do, South Korea

Loading trial locations.

About this study

This study is a prospective, single cohort, multi-center study of Vanguard PS system and will be conducted in Korea with 2 institutions. The study will be conducted over a period of 10 years. Patients will be followed at immediate post-op, 6 weeks, 6 months and 1 year, 3 years.

Total of 2 sites will be involved in this study. 50 cases on each sites and total of 100 subjects will be enrolled in the study.

Primary end-point will be KSS at 1 year post op and secondary end-points are Survivorship of the product, KSS, EQ5D, High-Flexion Knee Score, Radiographic Assessment, and any kind of complication including lost to follow up.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Painful and disabled knee joint resulting from osteoarthritis, rheumatoid arthritis, traumatic arthritis, where one or more compartments are involved.
  • Correction of varus, valgus, or posttraumatic deformity.
  • Correction or revision of unsuccessful osteotomy, arthrodesis, or failure of previous joint replacement procedure
  • Need to obtain pain relief and improve function
  • Ability and willingness of the patient to follow instructions, including control of weight and activity level
  • A good nutritional state of the patient, and
  • The patient must have reached full skeletal maturity (at least 18 years old).

Exclusion criteria

  • infection
  • sepsis
  • osteomyelitis
  • Uncooperative patient or patient with neurologic disorders who are incapable of following directions
  • Osteoporosis
  • Metabolic disorders which may impair bone formation
  • Osteomalacia
  • Distant foci of infections which may spread to the implant site
  • Rapid joint destruction, marked bone loss or bone resorption apparent on roentgenogram
  • Vascular insufficiency, muscular atrophy, neuromuscular disease
  • Incomplete or deficient soft tissue surrounding the knee

Treatment and study plan

Primary outcomes

  1. American Knee Society Score

    Time frame: 1 year Post Op

    Primary Endpoint: Knee Society Score (KSS) at 1 Year Postop

Secondary outcomes

  1. Survivorship

    Time frame: 3 years post op

    To access the number of patients with implants

  2. EQ-5D

    Time frame: 3 year post op

    Quality of life on patients

  3. Radiographic Assessment

    Time frame: 3 year Post Op

    Access on subsidence, migration, and radiolucency

  4. Complications

    Time frame: 3 year Post Op

    Any AEs to patients

Sponsors and collaborators

Lead sponsor

Zimmer Biomet

Industry

Registry information

Important dates

Study start
2012
Primary completion
2017
Study completion
2017
First posted
Jul 24, 2013
Registry last updated
Jun 26, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.